Scheduling note: August 6, 2026 is today, rather than tomorrow. Viatris is scheduled to discuss its second-quarter results on an 8:30 a.m. ET conference call.
Viatris enters the report with considerably more momentum—and a higher expectations bar—than it had at the beginning of the year. The shares closed August 5 at approximately $17.67, up about 42% year to date, following a strong first quarter and a more credible path toward sustained revenue and earnings growth.
The central question is no longer whether Viatris can stabilize its post-divestiture business. It is whether the company can turn Q1’s strong China growth, cost savings and pipeline execution into a repeatable growth model.
The best outcome would combine:
Published consensus sources point to roughly the following:
| Metric | Q2 2026 consensus | Q2 2025 actual | Approx. change |
|---|---|---|---|
| Revenue | $3.66 billion | $3.58 billion | +2% |
| Adjusted EPS | $0.61–$0.62 | $0.62 | Roughly flat |
Consensus estimates vary slightly by provider, with EPS centered around $0.61–$0.62 and revenue near $3.66 billion. (benzinga.com)
Viatris’ current full-year guidance is:
| 2026 guidance | Range | Midpoint |
|---|---|---|
| Revenue | $14.45B–$14.95B | $14.70B |
| Adjusted EBITDA | $4.15B–$4.45B | $4.30B |
| Adjusted EPS | $2.33–$2.47 | $2.40 |
| Free cash flow excluding transaction/restructuring costs | $1.95B–$2.35B | $2.15B |
Q1 produced revenue of $3.52 billion, adjusted EBITDA of $1.05 billion and adjusted EPS of $0.59. Revenue grew 3% operationally, while adjusted EBITDA grew 10%, reflecting strong operating leverage. (investor.viatris.com)
At consensus, first-half revenue would be approximately $7.18 billion, or 49% of the full-year midpoint. First-half adjusted EPS would be about $1.21, leaving $1.19 needed in the second half to reach the annual midpoint. The numbers therefore leave room for management to maintain guidance without requiring an aggressive second-half forecast, but the stock’s rally means a simple reiteration may not be enough to impress investors.
Greater China was the largest positive surprise in Q1:
The Q2 comparison is more demanding than Q1, and investors should focus on whether growth remains comfortably above the revised annual target. A moderation from 18% would be normal. A sharp deceleration, particularly if attributed to channel inventory or policy changes, would raise questions about the durability of the company’s fastest-growing geography.
Key questions:
Viatris generated $71 million of new-product revenue in Q1 against a full-year target of $450 million to $550 million. Management previously said this contribution would be weighted toward the second half.
The Q2 figure will help determine whether the required ramp is realistic. Investors should look for contributions from recent complex-generic launches and updates on planned launches such as generic Abilify Maintena, ferric carboxymaltose injection and the rotigotine patch.
A Q2 result only modestly above Q1 would place more pressure on the second half. Conversely, a meaningful sequential acceleration would validate management’s launch cadence and reduce dependence on China.
Q1 was notable for the gap between 3% operational revenue growth and 10% operational adjusted EBITDA growth. Adjusted gross margin remained around 56%, while adjusted SG&A declined to 22% of revenue from 24%.
Management attributed the result to disciplined cost control, early benefits from its enterprise-wide strategic review and some favorable expense timing. It expects roughly $120 million of net savings in 2026, forming part of a larger program intended to produce approximately $400 million of net annual savings by 2028.
The risk is that Q2 and second-half commercial and R&D spending begin to absorb some of the Q1 upside. Launch preparation for Gwyn Lo and fast-acting meloxicam, along with investment in cenerimod and selatogrel, should push expenses higher.
What matters most: Viatris does not need to repeat 10% EBITDA growth, but adjusted EBITDA should remain resilient enough to show that cost savings are structural—not simply postponed spending.
On July 29, the FDA approved Gwyn Lo, Viatris’ low-dose estrogen once-weekly contraceptive patch. The company expects commercial availability later in 2026 and previously estimated peak sales potential of at least $180 million. (investor.viatris.com)
The approval removes an important regulatory risk, but the near-term financial impact should be limited. The more important disclosures will be:
The approved label covers women with BMI below 30 kg/m², including women with BMI from 25 to under 30 without an additional limitation of use. That should support differentiation, although the patch remains a relatively small and promotion-sensitive part of the contraceptive market.
Two subsequent developments strengthen the pipeline narrative:
Other updates to watch include:
These programs underpin Viatris’ longer-term target of 3%–4% base-case revenue growth through 2030, with additional upside from business development, selatogrel and cenerimod. (investor.viatris.com)
The operating report should clarify two outstanding issues:
Supply constraints affected lower-margin antiretroviral products in Emerging Markets and certain products in Europe during Q1. Because those products are lower margin, revenue pressure may have less impact on EBITDA, but prolonged disruptions could weaken confidence in the company’s operational-growth narrative.
Q1 free cash flow was $348 million as reported and approximately $459 million excluding transaction and restructuring costs. Management continues to expect more than $2.5 billion of cash available for deployment during 2026.
The debate is how much goes toward:
Viatris returned only the dividend in Q1, after leaning more heavily into repurchases in 2025. With the shares now significantly higher, management may favor business development, but investors will want evidence of financial discipline rather than dealmaking simply to satisfy the 2030 growth framework.
A formal guidance increase is possible but not necessary for a positive reaction. Management declined to raise the ranges after Q1 because it was early in the year, despite saying it could potentially exceed internal expectations.
A constructive update would include some combination of:
Given the stock’s year-to-date appreciation, a bare reiteration accompanied by cautious commentary could be interpreted as disappointing.
Viatris enters Q2 from a position of strength: the base business is growing, Q1 showed meaningful operating leverage, and the company has delivered important pipeline wins with Gwyn Lo, Nefecon and fast-acting meloxicam.
The report’s most important financial read-through will be whether China growth, new-product revenue and cost savings can collectively support sustainable—not merely episodic—earnings growth. With the stock already up roughly 42% this year, investors are likely to demand more than an earnings beat. The key will be evidence that Viatris can carry its Q1 momentum into the second half while funding launches, generating cash and preserving upside to full-year guidance.